Nano Dimension (NNDM) investor relations material

Deal rationale and strategic fit

• The merger creates a publicly traded, AI-powered preventive health and diagnostics company leveraging Infinite's proprietary biological AI platform, Nano's capital base, and Nasdaq listing.

• Infinite brings a revenue-generating platform, large addressable market, and strong leadership, targeting earlier and more precise chronic disease detection.

• The platform combines clinical diagnostics, consumer longevity, pharma data, and enterprise health applications.

• The board will include representatives from both companies, with Infinite designating up to five of seven members, including three independents.

• Represents the culmination of a multi-phase strategic plan and a thorough review of ~20 companies for long-term value creation.

Financial terms and conditions

• Stock-for-stock merger values Infinite Epigenetics at $890 million, with Nano shares valued at a 20% premium to estimated net cash at closing.

• Existing Nano shareholders will retain a meaningful minority stake in the combined company.

• Pre-combination shareholders will receive contingent value rights tied to proceeds from legacy asset dispositions.

• Combined company expected to have over $400 million in cash at closing, providing financial flexibility.

• Signed term sheet on June 15, 2026; definitive agreement expected before July 31, 2026.

Synergies and expected cost savings

• Nano's capital and public platform will accelerate Infinite's growth, scale diagnostics, and advance its AI model.

• Shared biological data engine and proprietary AI model create compounding network effects and defensibility.

• Each processed test enhances the proprietary dataset, compounding value across multiple applications.

• Near-zero incremental cost for expanding into new disease markets and commercial applications.